Mucopolysaccharidoses (MPSs) are rare, heterogeneous inborn errors of metabolism (IEM) diagnosed through a combination of clinical, biochemical, and genetic investigations. The aim of this study was molecular characterization of the largest cohort of Iranian MPS patients (302 patients from 289 unrelated families), along with tracking their ethnicity and geographical origins. 185/289 patients were studied using an IEM‐targeted NGS panel followed by complementary Sanger sequencing, which led to the diagnosis of 154 MPS patients and 5 non‐MPS IEMs (diagnostic yield: 85.9%). Furthermore, 106/289 patients who were referred with positive findings went through reanalysis and confirmatory tests which confirmed MPS diagnosis in 104. Among the total of 258 MPS patients, 225 were homozygous, 90 harbored novel variants, and 9 had copy number variations. MPS IV was the most common type (34.8%) followed by MPS I (22.7%) and MPS VI (22.5%). Geographical origin analysis unveiled a pattern of distribution for frequent variants in ARSB (c.430G>A, c.962T>C [p.Leu321Pro], c.281C>A [p.Ser94*]), GALNS (c.319G>A [p.Ala107Thr], c.860C>T [p.Ser287Leu], c.1042A>G [p.Thr348Ala]), and IDUA (c.1A>C [p.Met1Leu], c.1598C>G [p.Pro533Arg], c.1562_1563insC [p.Gly522Argfs*50]). Our extensive patient cohort reveals the genetic and geographic landscape of MPS in Iran, which provides insight into genetic epidemiology of MPS and can facilitate a more cost‐effective, time‐efficient diagnostic approach based on the region‐specific variants.
Mucopolysaccharidoses (MPSs) are rare, heterogeneous inborn errors of
metabolism (IEM) diagnosed through a combination of clinical,
biochemical, and genetic investigations. The aim of this study was
molecular characterization of the largest cohort of Iranian MPS patients
(302 patients from 289 unrelated families), along with tracking their
ethnicity and geographical origins. 185/289 patients were studied using
an IEM-targeted NGS panel followed by complementary Sanger sequencing,
which led to the diagnosis of 154 MPS patients and 5 non-MPS IEMs
(diagnostic yield: 85.9%). Furthermore, 106/289 patients who were
referred with positive findings went through re-analysis and
confirmatory tests which confirmed MPS diagnosis in 104. Among the total
of 258 MPS patients, 225 were homozygous, and 9 had copy number
variations, and 90 had novel variants. MPS IV was the most common type
(34.8%) followed by MPS I (22.7%) and MPS VI (22.5%). Geographical
origin analysis unveiled a pattern of distribution for frequent variants
in ARSB (c.430G>A, c.962C>T,
c.281C>A), GALNS (c.319G>A,
c.860C>T, c.1042A>G), and IDUA
(c.1A>C, c.1598C>G). Our extensive patient
cohort reveals the genetic and geographic landscape of MPS in Iran,
which provides insight into the genetic epidemiology of MPS and can
facilitate a more cost-effective, time-efficient diagnostic approach
based on the region-specific variants.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.